Cargando…
Local immunotherapy with ONCOS-102 shapes harmful tumor associated CD68+ macrophages to become beneficial cells that correlate with increased overall survival
Autores principales: | Pesonen, Sari, Lundin, Johan, Linder, Nina, Turkki, Riku, Ristimäki, Ari, Joensuu, Timo, Kairemo, Kalevi, Partanen, Kaarina, Alanko, Tuomo, Jäger, Elke, Karbach, Julia, Wahle, Claudia, Hemminki, Akseli, Backman, Charlotta, von Euler, Mikael, Hakonen, Tiina, Ranki, Tuuli, Vuolanto, Antti, Jäderberg, Magnus, Zamarin, Dmitry |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4646108/ http://dx.doi.org/10.1186/2051-1426-3-S2-O16 |
Ejemplares similares
-
Phase I study with ONCOS-102 for the treatment of solid tumors – an evaluation of clinical response and exploratory analyses of immune markers
por: Ranki, Tuuli, et al.
Publicado: (2016) -
Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8(+) T-cell response, prominent infiltration of CD8(+) lymphocytes and Th1 type polarization
por: Ranki, Tuuli, et al.
Publicado: (2014) -
Gene expression analysis of tumors demonstrates an induction of Th1 type immune response following intratumoral administration of ONCOS-102 in refractory solid tumor patients
por: Majumder, Mamun, et al.
Publicado: (2014) -
Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8(+) T-cell response and robust cellular and transcriptional immune activation at tumor site in a patient with ovarian cancer
por: Vassilev, L, et al.
Publicado: (2015) -
Toxicological and bio-distribution profile of a GM-CSF-expressing, double-targeted, chimeric oncolytic adenovirus ONCOS-102 – Support for clinical studies on advanced cancer treatment
por: Kuryk, Lukasz, et al.
Publicado: (2017)